Glycomic and Proteomic Profiling of Pancreatic Cyst Fluids Identifies Hyperfucosylated Lactosamines on the N-linked Glycans of Overexpressed Glycoproteins*
暂无分享,去创建一个
Milos V Novotny | M. Novotny | B. Mann | C. Schmidt | M. House | Michael G House | C Max Schmidt | J. Goetz | John A. Goetz | John A Goetz | Benjamin F Mann
[1] David H Perlman,et al. Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. , 2009, Analytical chemistry.
[2] C. McCulloch,et al. Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. , 2007, AJR. American journal of roentgenology.
[3] N. Rofsky,et al. Prevalence of Incidental Pancreatic Cysts in the Adult Population on MR Imaging , 2010, The American Journal of Gastroenterology.
[4] R. Dwek,et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. , 2007, Glycobiology.
[5] H. Ueno,et al. The Usefulness of Serial Changes in Serum CA19-9 Levels in the Diagnosis of Pancreatic Cancer , 2000, Pancreas.
[6] R. Geyer,et al. Carbohydrate structure of human pancreatic elastase 1. , 1991, The Biochemical journal.
[7] M. Ohmuraya,et al. Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor , 2009, Molecular Cancer Research.
[8] Bhavinkumar B. Patel,et al. Proteomic Analyses of Pancreatic Cyst Fluids , 2009, Pancreas.
[9] Yehia Mechref,et al. Solid-phase permethylation of glycans for mass spectrometric analysis. , 2005, Rapid communications in mass spectrometry : RCM.
[10] J. Calam,et al. Interactions of pancreatic secretory trypsin inhibitor in small intestinal juice: its hydrolysis and protection by intraluminal factors. , 1990, Clinica chimica acta; international journal of clinical chemistry.
[11] CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials , 2005, British Journal of Cancer.
[12] S. Hakomori,et al. Novel fucolipids accumulating in human adenocarcinoma. II. Selective isolation of hybridoma antibodies that differentially recognize mono-, di-, and trifucosylated type 2 chain. , 1984, The Journal of biological chemistry.
[13] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[14] Yehia Mechref,et al. Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. , 2010, Analytical chemistry.
[15] J. Neoptolemos,et al. Prognosis of Resected Ampullary Adenocarcinoma by Preoperative Serum CA19-9 Levels and Platelet-Lymphocyte Ratio , 2008, Journal of Gastrointestinal Surgery.
[16] M. Monden,et al. Molecular mechanism involved in increased expression of sialyl Lewis antigens in ductal carcinoma of the pancreas. , 1999, Journal of experimental & clinical cancer research : CR.
[17] L. Mare,et al. Suppression of beta 1,3galactosyltransferase beta 3Gal-T5 in cancer cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines and sialyl-Lewis x on O-glycans. , 2004, European journal of biochemistry.
[18] M. Dwek,et al. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[19] U. Stenman,et al. Application of proteomic technology in identifying pancreatic secretory trypsin inhibitor variants in urine of patients with pancreatitis. , 2006, Clinical chemistry.
[20] Yehia Mechref,et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. , 2008, Clinical chemistry.
[21] G. Badger,et al. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. , 2011, Gastrointestinal endoscopy.
[22] S. Hakomori,et al. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. , 1986, Cancer research.
[23] M. Hollingsworth,et al. The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays* , 2009, Molecular & Cellular Proteomics.
[24] O. B. Schaffalitzky de Muckadell,et al. Comparison of Plasma Tu-M2-PK and CA19-9 in Pancreatic Cancer , 2010, Pancreas.
[25] P. Lescuyer,et al. Role of proteomics to differentiate between benign and potentially malignant pancreatic cysts. , 2011, Journal of proteome research.
[26] Y. Mechref,et al. Alterations in the serum glycome due to metastatic prostate cancer. , 2007, Journal of proteome research.
[27] T. Nakagawa,et al. Biological function of fucosylation in cancer biology. , 2007, Journal of biochemistry.
[28] U. Stenman. Tumor-associated trypsin inhibitor. , 2002, Clinical chemistry.
[29] M. Shah,et al. Serum fucosylation changes in oral cancer and oral precancerous conditions , 2008, Cancer.
[30] Y. Mechref,et al. ProteinQuant Suite: a bundle of automated software tools for label-free quantitative proteomics. , 2008, Rapid communications in mass spectrometry : RCM.
[31] L. A. van der Waaij,et al. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. , 2005, Gastrointestinal endoscopy.
[32] R. Kannagi,et al. Fucosylated type‐2 chain polylactosamine antigens in human lung cancer , 1988, International journal of cancer.
[33] M. Sahin-Tóth,et al. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: Identity with Rinderknecht's enzyme Y , 2007, Proceedings of the National Academy of Sciences.
[34] H. Mischinger,et al. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA. , 1997, Hepato-Gastroenterology.
[35] T. Oda,et al. Overexpression of Sialyl Lewis x Antigen Is Associated with Formation of Extratumoral Venous Invasion and Predicts Postoperative Development of Massive Hepatic Metastasis in Cases with Pancreatic Ductal Adenocarcinoma , 2002, Pathobiology.
[36] Y. Tian,et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[37] Michelle A. Anderson,et al. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. , 2011, Journal of proteome research.
[38] Ziding Feng,et al. Glycosylation Variants of Mucins and CEACAMs As Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms , 2010, Annals of surgery.
[39] N. Malats,et al. Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients , 2011, European Journal of Epidemiology.
[40] Osamu Ishikawa,et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation , 2006, International journal of cancer.
[41] Kerby Shedden,et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. , 2007, Journal of proteome research.
[42] William E Grizzle,et al. Serum Biomarker Panels for the Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.
[43] J. Samra,et al. CLASSIFICATION OF PANCREATIC CYSTIC LESIONS USING SELDI‐TOF MASS SPECTROMETRY , 2007, ANZ journal of surgery.
[44] E. Małecka-Panas,et al. Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis , 2011, Pancreatology.
[45] B. Domon,et al. Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. , 1988, Biochemistry.
[46] J. Dagorn,et al. Clinical assessment compared with cyst fluid analysis in the differential diagnosis of cystic lesions in the pancreas. , 1996, Surgery.
[47] P. Banks,et al. Practice Guidelines in Acute Pancreatitis , 2006, The American Journal of Gastroenterology.
[48] W. Alley,et al. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. , 2012, Journal of proteome research.
[49] S. Hanash,et al. A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.